TSX closed
Loading markets…

Advertisement

Stocks

Why Rakovina Therapeutics Inc stock plummeted yesterday

By Wealth Awesome -

This move is archived. Current quotes and coverage live on the stock page.

Stocks & ETFs:RKV.V

Follow RKV

Photos provided by Pexels

Rakovina Therapeutics Inc faced a significant downturn in its stock price, shedding over 20% in value.

In yesterday's trading session, Rakovina Therapeutics Inc (RKV.V) experienced a sharp decline, closing at CA$0.17 after falling 20.45%. This drop raises concerns about the company's current financial health and market positioning.

Advertisement

Rakovina Therapeutics Inc

RKV.V

Full stock page →

RKV.V

Rakovina Therapeutics Inc

Source:WealthAwesomeWealthAwesome
↑ $0.14 (145.00%)
120 day period
$0.10$0.21$0.32Apr 2Jun 29Sep 30

Market cap

$6.23M

52W high

$0.36

52W low

$0.09

1W change

-2.00%

Beta

-0.10

Analyst Price Targets

Based on analyst covering RKV · as of Sep 17, 2026

📈

Wall Street analysts forecast RKV stock price to rise 2.0% over the next 12 months.

Consensus

Neutral

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$0.25

+2.0% Upside

Current Price

C$0.24

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on RKV's historical volatility

HistoricalForecast68%95%
C$0.03C$0.66C$1.29C$1.92C$2.55C$3.18TodayMay 15Jul 22Sep 30Nov 12Dec 26Feb 7

30-Day Vol

197.2%

Annualized

90-Day Vol

151.3%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

C$0.29

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$0.26C$0.13 – C$0.51
60 trading daysC$0.28C$0.11 – C$0.72
90 trading daysC$0.29C$0.09 – C$0.95

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Investor takeaway: Investors should closely monitor Rakovina's financial updates and market strategies, especially after such a steep decline.

-20.45%

Rakovina's stock price plummeted significantly, reflecting investor concerns about the company's financial stability.

Bull case

If Rakovina can effectively leverage its recent advancements in AI-derived drug candidates, there may be potential for recovery and future growth. Investors could see a turnaround if the company capitalizes on these innovations.

Bear case

Continued financial losses and a lack of positive news could lead to further declines. It's essential for investors to evaluate their positions carefully and consider the risks involved.

Stock Performance Overview

Advertisement

Rakovina Therapeutics Inc's stock fell by 20.45% in yesterday's session, closing at CA$0.17. This significant drop is concerning for investors, especially given the company's market cap of approximately CA$4.27 million. The lack of recent positive news may have contributed to the sell-off.

Financial Health and Future Outlook

With no recent updates on financial performance or strategic initiatives, investors may be left questioning the sustainability of Rakovina's business model. The company's previous announcements regarding R&D expenses and private placements have not translated into market confidence, leading to this steep decline. For more insights, check out the latest on Rakovina's financial results.

Investor Considerations

Given the recent performance, investors should be cautious. Monitoring upcoming financial reports and any strategic announcements will be crucial for assessing whether Rakovina can recover from this setback. For those interested in the biotech sector, it's important to weigh the risks against potential rewards before making investment decisions. Additional details can be found on Rakovina's stock page.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: September 1, 2026
Last Updated: October 1, 2026

Core portfolio

Awesome Portfolio™

15.1% a year since 2017, against 9.9% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+15.1%

Awesome Portfolio™

+9.9%

S&P/TSX

+5.2 pp better a year

Total return

+260%

Awesome Portfolio™

+137%

S&P/TSX

+123 pp better than the TSX

2017-07-31 to 2026-09-17, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-17
-11.7%42.8%97.2%151.6%206.0%260.4%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement